Accrued liabilities consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
|
December 31, |
|
(in thousands) |
|
2025 |
|
|
2024 |
|
Employee-related expenses, including Restructuring Liability (Note 12) |
|
$ |
11,136 |
|
|
$ |
5,852 |
|
Professional fees |
|
|
1,615 |
|
|
|
1,461 |
|
Clinical expenses |
|
|
79 |
|
|
|
3,835 |
|
Manufacturing expenses |
|
|
50 |
|
|
|
516 |
|
Research and development expenses |
|
|
83 |
|
|
|
872 |
|
Accrued up-front license payment (Note 10) |
|
|
45,000 |
|
|
|
— |
|
Other |
|
|
141 |
|
|
|
356 |
|
Total accrued liabilities |
|
$ |
58,104 |
|
|
$ |
12,892 |
|
|